The University of North Carolina at Chapel Hill has been named a Designated Scleroderma Research and Treatment Center by the National Scleroderma Foundation. This accolade positions UNC among the two centers in the state to receive such an esteemed recognition.
The acknowledgment highlights UNC’s proficiency in providing care for individuals affected by scleroderma, an autoimmune condition characterized by inflammation and fibrosis, leading to thickening of the skin and other body areas. According to the National Scleroderma Foundation, the condition affects around 300,000 people in the United States. It impacts mostly women between the ages of 30 and 50.
UNC’s multi-disciplinary team, comprising dedicated rheumatologist, pulmonologists, cardiologists, dermatologists and gastroenterologists, is led by Nicole Orzechowski, DO, RhMSUS who serves as the site’s clinical and research lead. Beyond their expertise in providing comprehensive care for scleroderma patients, this accomplished team is actively contributing to the advancement of care options through ongoing scleroderma-related research.
“This designation is a testament to our commitment to excellence in the care of patients with scleroderma,” Dr. Orzechowski said. “Our highly experienced multidisciplinary team looks forward to continuing this important work and remains dedicated to improving the lives of people living with this complex and challenging condition.”
As a Scleroderma Research and Treatment Center, UNC will continue to actively share knowledge about scleroderma advancements with the public and healthcare providers. Learn more about the patient care we provide here.